Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19
| | | |

Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19

On Apr. 28, 2020, Sarepta Therapeutics announced the Company and the USAMRIID, the Department of Defense’s lead laboratory…

Ichor announced its TriGrid Delivery System is being utilized for delivery in non-human primates of a COVID-19 DNA vaccine being developed by Naval Medical Research Center
| | | |

Ichor announced its TriGrid Delivery System is being utilized for delivery in non-human primates of a COVID-19 DNA vaccine being developed by Naval Medical Research Center

On Apr. 27, 2020, Ichor announced that its TriGrid Delivery System is being utilized for delivery in non-human…

Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers
| | | | |

Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers

On Apr. 27, 2020, Merck and the Institute for Systems Biology announced a new research collaboration to investigate…

Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
| | | | |

Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome

On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…